Pooled effect size (ES) and pooled standardised response mean (SRM) for steroid injections in tendonitis according to the comparator
Comparator | Outcome | Week 1–3 | Week 4–8 | Week 12–24 | Week 48 |
All | Pain ES | 1.18 (0.27 to 2.09) | 1.30 (0.55 to 2.04) | −0.38 (−0.85 to 0.08) | 0.07 (−0.60 to 0.75) |
Pain SRM | 2.45 (1.10 to 3.80) | 0.96 (0.63 to 1.30) | 0.10 (−0.12 to 0.33) | −0.28 (−0.53 to −0.03) | |
Function ES | 0.20 (−0.30 to 0.70) | 0.66 (0.03 to 1.30) | −0.27 (−0.49 to −0.04) | 0.00 (−0.27 to 0.27) | |
Function SRM | 0.88 (0.32 to 1.44) | 1.06 (0.45 to 1.66) | −0.07 (−0.39 to 0.25) | −0.47 (−0.72 to −0.22) | |
Placebo | Pain ES | 1.89 (0.20 to 3.59) | 1.67 (0.56 to 2.78) | −0.45 (−1.01 to 0.11) | 0.25 (−0.82 to 1.32) |
Pain SRM | 2.52 (0.58 to 4.45) | 1.16 (0.79 to 1.53) | 0.21 (−0.09 to 0.50) | −0.15 (−0.51 to 0.20)* | |
Function ES | 0.20 (−0.30 to 0.70)* | 0.41 (−0.24 to 1.07) | −0.17 (−0.45 to 0.11) | 0.00 (−0.37 to 0.37)* | |
Function SRM | 1.08 (0.30 to 1.85) | 1.57 (0.55 to 2.59) | 0.09 (−0.26 to 0.45)* | −0.36 (−0.72 to 0.00)* | |
Physiotherapy | Pain ES | 0.64 (−0.18 to 1.47) | 0.51 (0.19 to 0.84) | −0.83 (−1.18 to −0.47)* | −0.74 (−1.10 to −0.39)* |
Pain SRM | 1.48 (1.08 to 1.87)* | 1.19 (0.84 to 1.55) | −0.04 (−0.39 to 0.31)* | −0.40 (−0.76,−0.05)* | |
Function ES | NE | NE | NE | NE | |
Function SRM | 1.20 (0.82 to 1.58)* | 1.15 (0.80 to 1.51) | −0.23 (−0.58 to 0.12)* | −0.57 (−0.93 to −0.22)* | |
NSAID | Pain ES | −0.04 (−0.90 to 0.82)* | 0.95 (−1.31 to 3.21) | 0.42 (0.03 to 0.80)* | 0.42 (0.03 to 0.80)* |
Pain SRM | 2.88 (−2.64 to 8.40) | 0.26 (−0.16 to 0.68) | NE | NE | |
Function ES | NE | 1.37 (0.94 to 1.79)* | −0.46 (−0.84 to −0.07)* | 0.00 (−0.38 to 0.38)* | |
Function SRM | 0.10 (−0.45 to 0.66)* | −0.04 (−0.45 to 0.38) | NE | NE |
Results are presented as effect (95% CI). Significant results are in bold type.
*One study.
NE, not estimable; NSAID, non-steroidal anti-inflammatory drug.